PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia

Detalhes bibliográficos
Autor(a) principal: Ferreira,Carlos Eduardo dos Santos
Data de Publicação: 2012
Outros Autores: Fonseca,Francisco Antônio Helfenstein, Mangueira,Cristóvão Luis Pitangueira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Einstein (São Paulo)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024
Resumo: This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.
id IIEPAE-1_53215cf182d0de34a92192511570985f
oai_identifier_str oai:scielo:S1679-45082012000400024
network_acronym_str IIEPAE-1
network_name_str Einstein (São Paulo)
repository_id_str
spelling PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemiaDyslipidemiasLipoproteinsCholesterol, LDLThis is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.Instituto Israelita de Ensino e Pesquisa Albert Einstein2012-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024einstein (São Paulo) v.10 n.4 2012reponame:Einstein (São Paulo)instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)instacron:IIEPAE10.1590/S1679-45082012000400024info:eu-repo/semantics/openAccessFerreira,Carlos Eduardo dos SantosFonseca,Francisco Antônio HelfensteinMangueira,Cristóvão Luis Pitangueiraeng2013-01-22T00:00:00Zoai:scielo:S1679-45082012000400024Revistahttps://journal.einstein.br/pt-br/ONGhttps://old.scielo.br/oai/scielo-oai.php||revista@einstein.br2317-63851679-4508opendoar:2013-01-22T00:00Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)false
dc.title.none.fl_str_mv PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
title PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
spellingShingle PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
Ferreira,Carlos Eduardo dos Santos
Dyslipidemias
Lipoproteins
Cholesterol, LDL
title_short PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
title_full PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
title_fullStr PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
title_full_unstemmed PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
title_sort PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
author Ferreira,Carlos Eduardo dos Santos
author_facet Ferreira,Carlos Eduardo dos Santos
Fonseca,Francisco Antônio Helfenstein
Mangueira,Cristóvão Luis Pitangueira
author_role author
author2 Fonseca,Francisco Antônio Helfenstein
Mangueira,Cristóvão Luis Pitangueira
author2_role author
author
dc.contributor.author.fl_str_mv Ferreira,Carlos Eduardo dos Santos
Fonseca,Francisco Antônio Helfenstein
Mangueira,Cristóvão Luis Pitangueira
dc.subject.por.fl_str_mv Dyslipidemias
Lipoproteins
Cholesterol, LDL
topic Dyslipidemias
Lipoproteins
Cholesterol, LDL
description This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.
publishDate 2012
dc.date.none.fl_str_mv 2012-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1679-45082012000400024
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
dc.source.none.fl_str_mv einstein (São Paulo) v.10 n.4 2012
reponame:Einstein (São Paulo)
instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
instname_str Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron_str IIEPAE
institution IIEPAE
reponame_str Einstein (São Paulo)
collection Einstein (São Paulo)
repository.name.fl_str_mv Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
repository.mail.fl_str_mv ||revista@einstein.br
_version_ 1752129906712510464

Registros relacionados